Sean Duffy Sells 14,158 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,158 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $20.00, for a total transaction of $283,160.00. Following the completion of the transaction, the chief executive officer directly owned 394,603 shares of the company’s stock, valued at approximately $7,892,060. The trade was a 3.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Omada Health Trading Up 10.5%

OMDA stock opened at $20.89 on Friday. The stock has a 50-day moving average price of $16.51 and a two-hundred day moving average price of $14.85. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The stock has a market cap of $1.24 billion and a PE ratio of -77.37.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Citizens Jmp upped their price target on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded shares of Omada Health from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of Omada Health in a research report on Friday, May 8th. Finally, Wells Fargo & Company boosted their price target on shares of Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Trading of Omada Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMDA. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Omada Health in the 4th quarter valued at about $1,222,000. Divisadero Street Capital Management LP acquired a new stake in Omada Health in the 3rd quarter valued at about $30,510,000. a16z Perennial Management L.P. acquired a new stake in Omada Health in the 4th quarter valued at about $2,480,000. Madryn Asset Management LP bought a new position in Omada Health during the fourth quarter worth about $9,212,000. Finally, Independent Advisor Alliance acquired a new position in Omada Health during the fourth quarter worth approximately $717,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.